The impact of pneumococcal conjugate vaccines on otitis media-Can we extrapolate to pneumonia?

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Pneumococcal conjugate vaccines (PCVs) have significant efficacy in preventing acute otitis media caused by vaccine-type pneumococcal serotypes. This article questions whether experiences with pneumococcal otitis can be applied to pneumococcal pneumonia, and examines whether PCVs have a class effect, meaning do different PCVs offer equivalent protection against the same outcome of pneumococcal disease. While PCVs appear to have a class effect in general, variability in serotype-specific antibody concentrations makes extrapolation from one vaccine to another difficult. Antibody concentrations or measurements of antibody functionality may provide a means to anticipate a predicted outcome in pneumococcal pneumonia for certain emergent vaccine candidates.

Original languageEnglish
Pages (from-to)B16-B18
JournalVaccine
Volume26
Issue numberSUPPL. 2
DOIs
StatePublished - 16 Jun 2008

Keywords

  • Antibody
  • Otitis
  • Vaccine

Fingerprint

Dive into the research topics of 'The impact of pneumococcal conjugate vaccines on otitis media-Can we extrapolate to pneumonia?'. Together they form a unique fingerprint.

Cite this